TG Therapeutics Stock: Riding a Wave of Commercial Success

Robust Financial Performance and Upward Revision

TG Therapeutics is demonstrating extraordinary momentum, largely driven by the remarkable performance of its flagship therapy. While numerous pharmaceutical companies face growth challenges, this biotechnology specialist is delivering impressive results and providing shareholders with dual benefits. The critical question for investors is whether this represents a sustainable shift in the company’s trajectory.

The company’s primary revenue driver, BRIUMVI, is rapidly establishing itself as a commercial success story. TG Therapeutics reported total second-quarter 2025 revenue of $141.1 million, with U.S. sales of BRIUMVI contributing $138.8 million to this figure. This represents a substantial 91 percent year-over-year increase, highlighting the therapy’s accelerating market adoption for multiple sclerosis treatment.